Eli Lilly offers cut-price deal on Mounjaro weight-loss jab in UK
The cost of the weight-loss injection Mounjaro is set for a shake-up in Britain, with drugmaker Eli Lilly introducing a discount for UK pharmacies after a steep rise in prices triggered alarm among patients and providers.
From Monday, the maximum 15mg dose of Mounjaro will carry a suggested price of £247.50 per month. That’s lower than the £330 Eli Lilly had originally put forward, but still more than double the current £122 cost.
Pharmacies have been told the saving amount to save £83 on the top dose, according to documents.
Lower doses, ranging from 2.5mg to 12.5mg, will see smaller reductions.
The price hike stems from pressure in Washington. U.S. President Donald Trump urged American pharmaceutical firms to raise prices abroad to keep domestic costs down. Eli Lilly’s UK arm followed suit, sparking panic-buying.
Pharmaceutical giant @EliLillyandCo has announced it will increase the price of diabetes and weight loss drug Mounjaro by up to 170%, and halt shipments of the drug to the UK until the new price comes into effect.
Read our letter to the company pic.twitter.com/kGBn7aVVKn
— Business and Trade Committee (@CommonsBTC) August 28, 2025
Patients rushed to secure supplies, leaving high street chains such as Boots, Lloyds and Superdrug short of stock. The company temporarily suspended wholesaler sales to stabilise supplies.
With the Eli Lilly Mounjaro price jump looming, some users have jumped ship. Rival drug Wegovy, widely seen as more affordable, has enjoyed a sales surge; one supplier reported a staggering 2,600% increase.
Experts fear patients could be priced out. Many already rely on private prescriptions, as the NHS rollout of weight-loss jabs is expected to take more than a decade to reach everyone eligible.
Doctors have also warned against counterfeit injections being sold online, preying on those “already struggling to pay for it”.
Eli Lilly responded: “We are working with private providers on commercial arrangements to maintain affordability and expect these to be passed onto patients when the change is effective on 1st September.
We are already seeing providers respond in different ways to the list price change, with a range of options available for eligible patients.
We also want to work in partnership with the government to expand NHS access for eligible patients, building on the commitments in the government’s 10-year plan.”
Branded the “King Kong” of weight-loss treatments, weight loss jab Mounjaro has transformed the lives of some patients but comes with risks.
Milder side effects include nausea, indigestion, and heartburn. More serious complications can involve gallstones, hypoglycaemia, or pancreatitis, according to NHS guidance.
